GlassScriptPhysician profile
Jason Thomas Barney
NPI 1932775889
$1,447.47
in general payments reported to CMS, 2019-2025
15 companies · $1,447 in 2025
The $1,447 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,447.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $510.51 | 2025 | Repatha, Evenity |
| Kowa Pharmaceuticals America, INC. | $206.32 | 2025 | Zoryve |
| Abbvie INC. | $127.97 | 2025 | |
| Novartis Pharmaceuticals Corporation | $116.15 | 2025 | |
| Ionis Pharmaceuticals, INC. | $94.69 | 2025 | Tryngolza |
| Madrigal Pharmaceuticals | $83.10 | 2025 | Rezdiffra |
| Lilly USA, LLC | $82.46 | 2025 | Mounjaro, Zepbound |
| Chiesi USA, INC. | $62.93 | 2025 | Juxtapid |
| Esperion Therapeutics, INC. | $43.88 | 2025 | Nexletol |
| Exact Sciences Corporation | $30.49 | 2025 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $21.75 | 2025 | Evkeeza |
| Actelion Pharmaceuticals US, INC. | $18.62 | 2025 | Uptravi, Opsumit |
| Otsuka America Pharmaceutical, INC. | $18.20 | 2025 | Rexulti |
| Ibsa Pharma INC. | $16.23 | 2025 | Flector, Licart, Tirosint |
| Novo Nordisk INC | $14.17 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Barney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.